Summary
European leaders recognize the vulnerability of critical supply chains, particularly in pharmaceuticals, where 70% of generic drugs are imported from outside Europe due to cost optimization. The COVID-19 pandemic exposed these weaknesses, highlighting the need for resilience over cost. While reshoring all supply chains is unrealistic, there's a call for economic incentives to build infrastructure in Europe and for governments to collaborate on solutions, as rising costs threaten the security of critical medicine supply.